Treatments being tested
Clinical trials open to people with bowel cancer
Every trial here is a live record from ClinicalTrials.gov, the public registry every trial must be listed on before it starts. Statuses are re-checked against the registry every day or two, because a list that says a closed trial is recruiting is worse than no list at all.
Listing a trial is not a recommendation, and this site has no connection to any of them. Whether a trial is right for you, and whether you would be eligible, is a conversation for your own oncology team.
What these filters mean
Genotype
These are the things that make a tumour unusual, so leave them alone unless one of them is yours. Nothing selected shows every trial. Wild-type and pMMR are the ordinary results and have no button of their own: they would match almost everybody, so they would narrow nothing. Selecting a mutation drops the trials that need the ordinary result instead â which is right, because those are the ones you could not join.
Which KRAS
Only relevant if your tumour is KRAS mutated. Your report will name the exact change, such as G12C or G12D; some newer drugs are built for one specific change and no other.
Each trial is tagged by reading its own eligibility criteria automatically, to make the list searchable. The tags summarise what the criteria mention — they are not a decision about whether you qualify, and where a tag and the criteria disagree, the criteria are right.
458 trials
Recruiting nowPhase 1
Open-label Phase 1b Study of Ulixertinib and Cetuximab or Ulixertinib in Combination With Cetuximab and Encorafenib in Patients With Unresectable or Metastatic Colorectal Cancer Who Have Previously Received EGFR or BRAF-directed Therapy
Recruiting nowPhase 1
Testing the Addition of an Anti-Cancer Drug, Abemaciclib, to the Usual Chemotherapy Treatment (5-Fluorouracil) for Metastatic, Refractory Colorectal Cancer
Recruiting nowPhase 1
YMN-136 Vaccine for Patients With Liver Metastasis of Colorectal Cancer Progressing After Third-Line Treatment
Recruiting nowPhase 1
Phase 1 Study to Investigate TCRTs KRAS Mutation in Unresectable, Advanced, and/or Metastatic Solid Tumors
Recruiting nowPhase 1
Study of ctDNA Guided Change in Tx for Refractory Minimal Residual Disease in Colon Adenocarcinomas
Recruiting nowPhase 1
A Study of STRO-004 in Adults With Refractory/Recurrent Metastatic Cancer
Recruiting nowPhase 1
A Phase 1a/1b, First-Time-in-Human Study of CT-202, a Nectin-4 Directed Bispecific Antibody, in Participants With Recurring Triple Negative Breast, Colorectal, Urothelial Cancers
Recruiting nowPhase 1
A Study of MRG007 (ARR-217) in Patients With Advanced Solid Tumors
Recruiting nowNot phased
Contact Radiotherapy for Rectal Cancer
Recruiting nowNot phased
Active Surveillance vs Adjuvant Chemoradiotherapy for Locally Resected Intermediate-Risk T1 Rectal Cancer
Recruiting nowNot phased
REsults of LOw Anterior Resections With or Without Preventive Stoma in Nonemergency Department
Recruiting nowNot phased
Total Meso-rectal Excision Versus Transanal Local Excision Followed by Radiotherapy for T2N0M0 Distal Rectal Cancer
Recruiting nowNot phased
D2 vs D3 Lymph Node Dissection for Left Colon Cancer
Recruiting nowNot phased
Safety of Mid and Low Rectal Cancer Surgery Without Dissection of the No.253 Lymph Node
Recruiting nowNot phased
Autologous Tumor-Infiltrating Lymphocyte (GT307) for Treatment of Patients With Advanced Colorectal Cancer